Cited 9 times in
Early response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 서창옥 | - |
dc.contributor.author | 장종희 | - |
dc.contributor.author | 장지은 | - |
dc.contributor.author | 정준원 | - |
dc.contributor.author | 현신영 | - |
dc.contributor.author | 황도유 | - |
dc.contributor.author | 김세훈 | - |
dc.contributor.author | 김수정 | - |
dc.contributor.author | 김유리 | - |
dc.contributor.author | 김윤덕 | - |
dc.contributor.author | 김진석 | - |
dc.contributor.author | 민유홍 | - |
dc.date.accessioned | 2015-01-06T16:23:52Z | - |
dc.date.available | 2015-01-06T16:23:52Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/98028 | - |
dc.description.abstract | Optimal treatment strategies for primary central nervous system lymphoma (PCNSL) have not been established. In this study, we investigated the treatment outcomes and prognostic factors of high-dose methotrexate, vincristine, and procarbazine (MVP) chemotherapy followed by an interim response-adapted intensification strategy in immunocompetent patients with PCNSL. We evaluated the evidence of infection with Epstein-Barr virus (EBV) in both brain tumor tissue and whole blood. Forty patients were retrospectively reviewed. Ten (25 %) patients who achieved complete response (CR) in the interim analysis did not receive any additional consolidation treatment after completion of planned high-dose MVP chemotherapy. Additional radiotherapy (n = 9) or autologous stem cell transplantation (ASCT) (n = 7) was performed in patients who did not achieve CR in the interim analysis. The median age was 55 years. The overall CR rate was 62.5 % (n = 25), and the objective response rate was 75.0 %. Two-year overall survival (OS) was 59.8 %, and 2-year progression-free survival was 47.1 %. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 47.5 and 32.5 % of patients, respectively. Treatment-related mortality was 15.0 % (n = 6), and four patients developed delayed neurotoxicity. There was no evidence of EBV-encoded RNA expression in brain tumor tissue. Ten (29.4 %) of 34 patients showed detectable EBV-DNA in whole blood. Poor performance status and EBV-DNA positivity in whole blood were significantly associated with inferior OS (p = 0.032, p = 0.023, respectively). We suggest that high-dose MVP chemotherapy followed by an early response-adapted intensification strategy may be effective and minimize the number of patients who receive radiotherapy or ASCT in the early course of treatment. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 211~219 | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Autografts | - |
dc.subject.MESH | Brain Neoplasms/metabolism | - |
dc.subject.MESH | Brain Neoplasms/mortality | - |
dc.subject.MESH | Brain Neoplasms/pathology | - |
dc.subject.MESH | Brain Neoplasms/therapy* | - |
dc.subject.MESH | Brain Neoplasms/virology | - |
dc.subject.MESH | DNA, Viral/metabolism | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Epstein-Barr Virus Infections/metabolism | - |
dc.subject.MESH | Epstein-Barr Virus Infections/mortality | - |
dc.subject.MESH | Epstein-Barr Virus Infections/pathology | - |
dc.subject.MESH | Epstein-Barr Virus Infections/therapy* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Gene Expression Regulation, Neoplastic/drug effects | - |
dc.subject.MESH | Gene Expression Regulation, Neoplastic/radiation effects | - |
dc.subject.MESH | Gene Expression Regulation, Viral/drug effects | - |
dc.subject.MESH | Gene Expression Regulation, Viral/radiation effects | - |
dc.subject.MESH | Herpesvirus 4, Human* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymphoma/metabolism | - |
dc.subject.MESH | Lymphoma/mortality | - |
dc.subject.MESH | Lymphoma/pathology | - |
dc.subject.MESH | Lymphoma/therapy* | - |
dc.subject.MESH | Lymphoma/virology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Methotrexate/administration & dosage | - |
dc.subject.MESH | Methotrexate/adverse effects | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Procarbazine/administration & dosage | - |
dc.subject.MESH | Procarbazine/adverse effects | - |
dc.subject.MESH | RNA, Viral/metabolism | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Stem Cell Transplantation* | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Vincristine/administration & dosage | - |
dc.subject.MESH | Vincristine/adverse effects | - |
dc.title | Early response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurosurgery (신경외과학) | - |
dc.contributor.googleauthor | Yu Ri Kim | - |
dc.contributor.googleauthor | Se Hoon Kim | - |
dc.contributor.googleauthor | Jong Hee Chang | - |
dc.contributor.googleauthor | Chang-Ok Suh | - |
dc.contributor.googleauthor | Soo-Jeong Kim | - |
dc.contributor.googleauthor | Yundeok Kim | - |
dc.contributor.googleauthor | Doh Yu Hwang | - |
dc.contributor.googleauthor | Ji Eun Jang | - |
dc.contributor.googleauthor | Shin Young Hyun | - |
dc.contributor.googleauthor | June-Won Cheong | - |
dc.contributor.googleauthor | Yoo Hong Min | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.identifier.doi | 10.1007/s00277-013-1853-7 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01919 | - |
dc.contributor.localId | A03470 | - |
dc.contributor.localId | A03477 | - |
dc.contributor.localId | A03729 | - |
dc.contributor.localId | A04381 | - |
dc.contributor.localId | A04457 | - |
dc.contributor.localId | A00610 | - |
dc.contributor.localId | A00633 | - |
dc.contributor.localId | A00790 | - |
dc.contributor.localId | A01017 | - |
dc.contributor.localId | A01407 | - |
dc.contributor.localId | A00779 | - |
dc.relation.journalcode | J00161 | - |
dc.identifier.eissn | 1432-0584 | - |
dc.identifier.pmid | 23903866 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00277-013-1853-7 | - |
dc.subject.keyword | Primary central nervous system lymphoma | - |
dc.subject.keyword | High-dose methotrexate | - |
dc.subject.keyword | Consolidation | - |
dc.subject.keyword | Complete response | - |
dc.subject.keyword | Epstein-Barr virus | - |
dc.contributor.alternativeName | Suh, Chang Ok | - |
dc.contributor.alternativeName | Chang, Jong Hee | - |
dc.contributor.alternativeName | Jang, Ji Eun | - |
dc.contributor.alternativeName | Cheong, June Won | - |
dc.contributor.alternativeName | Hyun, Shin Yong | - |
dc.contributor.alternativeName | Hwang, Doh Yu | - |
dc.contributor.alternativeName | Kim, Se Hoon | - |
dc.contributor.alternativeName | Kim, Soo Jeong | - |
dc.contributor.alternativeName | Kim, Yu Ri | - |
dc.contributor.alternativeName | Kim, Yun Deok | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.alternativeName | Min, Yoo Hong | - |
dc.contributor.affiliatedAuthor | Suh, Chang Ok | - |
dc.contributor.affiliatedAuthor | Chang, Jong Hee | - |
dc.contributor.affiliatedAuthor | Jang, Ji Eun | - |
dc.contributor.affiliatedAuthor | Cheong, June-Won | - |
dc.contributor.affiliatedAuthor | Hyun, Shin Yong | - |
dc.contributor.affiliatedAuthor | Hwang, Doh Yu | - |
dc.contributor.affiliatedAuthor | Kim, Se Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Soo Jeong | - |
dc.contributor.affiliatedAuthor | Kim, Yun Deok | - |
dc.contributor.affiliatedAuthor | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | Min, Yoo Hong | - |
dc.contributor.affiliatedAuthor | Kim, Yu Ri | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 93 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 211 | - |
dc.citation.endPage | 219 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, Vol.93(2) : 211-219, 2014 | - |
dc.identifier.rimsid | 54339 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.